A detailed history of Newbridge Financial Services Group, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Newbridge Financial Services Group, Inc. holds 75 shares of VKTX stock, worth $3,944. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75
Previous 75 -0.0%
Holding current value
$3,944
Previous $3,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Sep 11, 2024

SELL
$47.39 - $80.2 $1,184 - $2,005
-25 Reduced 25.0%
75 $3,000
Q1 2024

Apr 24, 2024

SELL
$17.4 - $94.5 $1,739 - $9,450
-100 Reduced 50.0%
100 $8,000
Q4 2023

Mar 28, 2024

BUY
$9.24 - $19.64 $924 - $1,964
100 Added 100.0%
200 $3,000
Q2 2023

Jul 21, 2023

BUY
$14.84 - $24.79 $1,484 - $2,479
100 New
100 $1,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Newbridge Financial Services Group, Inc. Portfolio

Follow Newbridge Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.